Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Key Points

• Loring Wolcott & Coolidge Fiduciary Advisors cut its Regeneron stake by 39.6% in the third quarter, selling 26,114 shares and retaining 39,761 shares worth approximately $30.15 million.
• Analyst sentiment remains positive, with Regeneron carrying a consensus “Moderate Buy” rating and an average price target of $846.28; TD Cowen and UBS recently raised their targets to $980 and $978, respectively.
• Regeneron reported strong latest quarterly results, with earnings and revenue exceeding expectations and revenue rising 16.7% year over year. However, insiders have sold 8,093 shares worth about $6.5 million over the past 90 days, and valuation concerns remain ahead of the next earnings report.

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 39.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,761 shares of the biopharmaceutical company's stock after selling 26,114 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in Regeneron Pharmaceuticals were worth $30,150,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of REGN. Kingswood Wealth Advisors LLC raised its position in Regeneron Pharmaceuticals by 17.6% during the 3rd quarter. Kingswood Wealth Advisors LLC now owns 870 shares of the biopharmaceutical company's stock worth $660,000 after buying an additional 130 shares during the last quarter. Samalin Investment Counsel LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $236,000. Signaturefd LLC lifted its stake in shares of Regeneron Pharmaceuticals by 20.9% in the 3rd quarter. Signaturefd LLC now owns 2,123 shares of the biopharmaceutical company's stock worth $1,610,000 after acquiring an additional 367 shares during the period. Citizens Financial Group Inc. RI boosted its holdings in shares of Regeneron Pharmaceuticals by 36.6% in the third quarter. Citizens Financial Group Inc. RI now owns 5,978 shares of the biopharmaceutical company's stock valued at $4,533,000 after acquiring an additional 1,602 shares in the last quarter. Finally, Simplicity Wealth LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 7.2% in the third quarter. Simplicity Wealth LLC now owns 1,257 shares of the biopharmaceutical company's stock valued at $954,000 after acquiring an additional 84 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on REGN. Argus upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $850.00 price target on the stock in a research note on Thursday, October 1st. Benchmark upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price objective for the company in a research report on Tuesday, July 7th. TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a "buy" rating in a research report on Wednesday, October 21st. Robert W. Baird lifted their price objective on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a "neutral" rating in a report on Friday, July 31st. Finally, UBS Group upgraded Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $660.00 to $978.00 in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $846.28.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Zoghbi sold 800 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at $512,550. This trade represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock valued at $6,506,845 in the last 90 days. Insiders own 6.97% of the company's stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: TD Cowen raised its price target to $980 from $960 while maintaining a positive view of Regeneron, signaling potential upside from current levels. TD Cowen raises target for Regeneron stock
• Positive Sentiment: Analysts and investors continue to point to Regeneron’s growth potential, including strong Dupixent performance and positive Phase 3 OPTIMA results for investigational pasatru in fibrodysplasia ossificans progressiva. The company is also working to build a broader global oncology business. Regeneron growth potential analysis
• Neutral Sentiment: Regeneron is scheduled to report quarterly results next week. Analysts expect earnings to grow, but the company reportedly lacks the typical combination of estimate revisions and other indicators associated with a likely earnings beat, creating uncertainty ahead of the release. Regeneron earnings expectations
• Neutral Sentiment: Recent coverage describes REGN as a relatively steady stock and notes that it gained in the prior session, although it lagged some competitors. This provides limited new information about the company’s fundamentals. Regeneron stock performance versus competitors
• Negative Sentiment: Valuation-related commentary asks whether Regeneron is priced too highly relative to pharmaceutical peers, which could limit near-term upside and encourage profit-taking ahead of earnings. Regeneron valuation versus rivals

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $805.02 on Monday. The firm has a market capitalization of $82.88 billion, a P/E ratio of 19.90, a PEG ratio of 1.36 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a one year low of $575.93 and a one year high of $859.34. The company's fifty day moving average is $791.86 and its two-hundred day moving average is $722.88. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to analysts' expectations of $3.82 billion. During the same period in the prior year, the company posted $12.81 EPS. The business's revenue for the quarter was up 16.7% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were issued a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.